Astellas to close Urogenix, shift urology research to Japan

Monday, August 6, 2012 02:09 PM

Astellas Pharma has decided to close Urogenix, an Astellas subsidiary and Durham, N.C.-based research facility focusing on drug discovery in the field of urology.

In March 2006, Astellas acquired this research facility from Dynogen Pharmaceuticals. Since then, Urogenix has evaluated the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. Urology continues to be one of Astellas' five focus therapeutic areas and upon this decision, Astellas will transfer research functions at Urogenix to Astellas' Tsukuba Research Center in Japan.

Urogenix currently employees 13 scientists and staff. The decision to transfer urology research activities to Japan will strengthen the company's commitment to optimizing its research and development resource allocation.

The closure will be completed by the end of December 2012.

Share:          
CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs